Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Role of prostate-specific antigen change ratio at initial biopsy as a novel decision-making marker for repeat prostate biopsy.

Lee JG, Bae SH, Choi SH, Kwon TG, Kim TH.

Korean J Urol. 2012 Jul;53(7):467-71. doi: 10.4111/kju.2012.53.7.467. Epub 2012 Jul 19.

2.

Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.

Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M.

J Urol. 2000 Apr;163(4):1144-8; discussion 1148-9.

PMID:
10737484
3.

Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer.

Fowler JE Jr, Bigler SA, Miles D, Yalkut DA.

J Urol. 2000 Mar;163(3):813-8.

PMID:
10687983
4.

Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.

Okegawa T, Kinjo M, Ohta M, Miura I, Horie S, Nutahara K, Higashihara E.

Int J Urol. 2003 Apr;10(4):201-6.

5.

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.

Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, Fisch M, Graefen M, Pummer K, Chun FK.

BJU Int. 2012 Jun;109(11):1627-35. doi: 10.1111/j.1464-410X.2011.10584.x. Epub 2011 Sep 21.

6.

Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.

Letran JL, Blase AB, Loberiza FR, Meyer GE, Ransom SD, Brawer MK.

J Urol. 1998 Aug;160(2):426-9.

PMID:
9679891
7.

Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy.

Uemura H, Nakamura M, Hasumi H, Sugiura S, Fujinami K, Miyoshi Y, Yao M, Kubota Y.

Int J Urol. 2004 Jul;11(7):494-500.

8.
10.
13.

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.

Roehrborn CG, Boyle P, Gould AL, Waldstreicher J.

Urology. 1999 Mar;53(3):581-9.

PMID:
10096388
14.

Prostate-specific antigen complexed to alpha(1)-antichymotrypsin in the early detection of prostate cancer.

Martínez M, España F, Royo M, Vera CD, Estellés A, Jiménez-Cruz JF, Medina P, Aznar J.

Eur Urol. 2000 Jul;38(1):85-90.

PMID:
10859447
15.

The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.

Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL.

BJU Int. 2012 Jul;110(1):36-42. doi: 10.1111/j.1464-410X.2011.10681.x. Epub 2011 Nov 15.

16.

Role of PSA and its indices in determining the need for repeat prostate biopsies.

Ukimura O, Durrani O, Babaian RJ.

Urology. 1997 Jul;50(1):66-72.

PMID:
9218021
17.

Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.

Hong SK, Oh JJ, Byun SS, Hwang SI, Choo MS, Lee SE.

BJU Int. 2012 Jul;110(2 Pt 2):E81-5. doi: 10.1111/j.1464-410X.2011.10764.x. Epub 2011 Nov 17.

18.
20.

[Indication of repeat prostate biopsy for the diagnosis of prostate cancer].

Hori J, Okuyama M, Azumi M, Kato Y, Saga Y, Hashimoto H, Tokumitsu M, Kakizaki H.

Hinyokika Kiyo. 2006 Nov;52(11):835-8; discussion 838-9. Japanese.

Supplemental Content

Support Center